This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Hello! Today, we talk about how much dang money some CEOs still make, despite the slowdown in the biotech industry. We also see Dupixent approved for a huge new indication, and more.
Read the rest…
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Hello! Today, we talk about how much dang money some CEOs still make, despite the slowdown in the biotech industry. We also see Dupixent approved for a huge new indication, and more.
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
